InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the full record of transactions filed by HAMED KAMAL. Director active across 1 company, notably Spero Therapeutics, Inc.. Aggregated, 5 reports have been logged. Split: 0 buy · 1 sell. Total volume traded: €47k. History available since 12 September 2022. The latest transaction was disclosed on 1 February 2024 (Attribution). Regulator: SEC (Form 4). The full history is free.
5 of 5 declarations